Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy
Bhagirathbhai Dholaria, Bipin N. Savani, Betty K. Hamilton, Betül Oran, Hien Liu, Martin S. Tallman, Stefan O. Ciurea, Noa G. Holtzman, Gordon L. Phillips, Steven M. Devine, Gabriel N. Mannis, Michael R. Grunwald, Frederick R. Appelbaum, Cesar Rodriguez, Firas El Chaer, Nina Shah, Shahrukh K. Hashmi, Mohamed A. Kharfan‐Dabaja, Zachariah DeFilipp, Mahmoud Aljurf, Alfadel Alshaibani, Yoshihiro Inamoto, Tania Jain, Navneet S. Majhail, Miguel‐Angel Perales, Mohamad Mohty, Mehdi Hamadani, Paul A. Carpenter, Arnon Nagler
Abstract
The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and nontransplant experts, was invited to develop clinically relevant frequently asked questions covering disease- and HCT-related topics. A systematic literature review was conducted to generate core recommendations that were graded based on the quality and strength of underlying evidence based on the standardized criteria established by the American Society of Transplantation and Cellular Therapy Steering Committee for evidence-based reviews. Allogeneic HCT offers a survival benefit in patients with intermediate- and high-risk AML and is currently a part of standard clinical care. We recommend the preferential use of myeloablative conditioning in eligible patients. A haploidentical related donor marrow graft is preferred over a cord blood unit in the absence of a fully HLA-matched donor. The evolving role of allogeneic HCT in the context of measurable residual disease monitoring and recent therapeutic advances in AML with regards to maintenance therapy after HCT are also discussed.